940307-96-0

Usage

Structure

Contains a cyclopropane ring, a hydroxyphenyl group, and a nitrile functional group.

Organic synthesis

Used as a building block for creating complex molecules.

Medicinal chemistry

Employed in the development of new drugs.

Biological activities

Exhibits potential for drug discovery and development.

Cancer treatment

Studied for its potential in treating cancer.

Inflammation

Investigated for its use in managing inflammation.

Other diseases

Explored for its possible applications in treating various diseases.

Versatility

Has a range of applications in both research and industry.

Upstream product

• 19924-43-7 3-methoxyphenylacetonitrile 
• 74205-01-9 1-(3-methoxyphenyl)cyclopropanecarbonitrile 

Downstream Products

• 1200397-43-8 1-(3-(2,6-dimethylbenzyloxy)phenyl)cyclopropanecarbonitrile 
• 1200397-44-9 1-(3-(2,6-dimethylbenzyloxy)phenyl)cyclopropanecarbaldehyde 
• 1200397-24-5 1-(3-(2,6-dimethylbenzyloxy)phenyl)cyclopropanecarboxylic acid 

Relevant academic research and scientific papers

COMPOUNDS AND METHOD FOR REDUCING URIC ACID

Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In Formula (I) m is 0, 1, 2, 3 or 4; n is 0 or 1; m + n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, methyl or ethyl and R12 is hydrogen or methyl, or R6 is hydroxy and R12 is hydrogen, or R6 is O and R12 is absent, or R6 and R12 together are -CH2CH2-. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of Formula (I) by a ring carbon; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl. The uric acid-lowering effects of the Compounds of Formula (I) are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, and cognitive impairment.

FUSED HETEROCYCLIC COMPOUND

The present invention provides a compound represented by the formula: wherein R1ais a hydrogen atom, R2a is a C1-6 alkyl group substituted by a group represented by-NR6a-CO-(CH2) n-SO2